Fighting nerve damage together 

An international expert panel published recommendations for diagnosis and management of diabetic neuropathy. Wörwag Pharma provides information on the current consensus recommendations for health care professionals.

Underestimated and serious – this is how experts describe diabetic neuropathy. Roughly one in three patients is affected by this nerve damage, which frequently manifests itself by sensory disturbances like tingling, burning, pain, numbness or reduced sensitivity in the feet. Although the disease affects the patients’ quality of life substantially and can have serious consequences, it is not recognized and often treated too late. To improve this, 15 internationally renowned neuropathy experts from all over the world met with the aim of developing consensus recommendations on the diagnosis and management of this disease. 

Existing guidelines of medical associations are inconsistent in some aspects. Moreover, they focus on the treatment of neuropathic pain. In the view of the expert panel the recommendations should be consistent, and the therapeutic approach should be more comprehensive. Therefore, after the evaluation of current evidence, the doctors published a consensus report, which recommends a therapy based on three cornerstones. 

The consensus report has now been published in the international journal “Diabetes Research and Clinical Practice”, the official journal of the International Diabetes Federation (IDF). 

Wörwag Pharma provides information on the current consensus recommendations for health care professionals. Read more >>

Reference
Ziegler D, Tesfaye S, Spallone V, Gurieva I, Al Kaabi J, Mankovsky B, Martinka E, Radulian G, Nguyen TK, Stirban AO, Tankova T, Varkonyi T, Freeman R, Kempler P, Boulton AJM. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Res Clin Pract. 2021 Sep 18:109063. doi: 10.1016/j.diabres.2021.109063. 

 

International Expert-Consensus
Press Contact
Kerstin Imbery-Will
Kerstin Imbery-WillPublic relations+49 4183 774623kerstin.imbery-will@woerwagpharma.com
Monika Wörwag
Monika WörwagCompany communicationmonika.woerwag@woerwagpharma.com